Xintela licenses human antibody technology for cancer therapy

Xintela AB (publ) today announced the company has licensed antibody technology for the development of human antibodies in diagnostics and therapy. The antibodies, directed to Xintela’s markers integrin 101 och integrin 111, are already adapted for human use. This means that Xintela saves both time and money and that Xintela’s cancer products can be tested […]

Xintela raises 17 million SEK in debt and equity

Xintela AB (publ) announces a directed share issue of approximately 10 million SEK and borrowing of 7 million SEK to strengthen its working capital for investment in Xintela’s development programs. The Board of Xintela, under the authorization adopted at the AGM on 18 May 2017, today decided to issue a total of 3,205,129 new shares, […]

Keld Søndergaard leaves Xintela’s Board of Directors

Xintela AB (publ) announces that Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons. Xintela’s larger shareholders, acting as an informal nomination committee, will consider potential replacement candidates to propose to the next Annual General Meeting. Keld Søndergaard was elected as a new member of the Board at the Annual General […]

Xintela building own GMP-facility for stem cell production

Xintela AB (publ) announces the company has decided to bring forward the construction of its own facility for production of equine and human stem cell-based ATMPs (Advanced Therapy Medicinal Products) at Medicon Village, Lund. Initially, stem cells will be produced for clinical studies in horses. After careful evaluation of available options, Xintela has decided to […]

Xintela recruits Liselotte Theorell as Director Product Development and Quality Management

Xintela AB (publ) announces that the company has recruited Liselotte Theorell as Director Product Development and Quality Management. The recruitment is an important step towards the production of stem cells under GMP (Good Manufacturing Practice) for upcoming clinical studies. “Liselotte is one of few persons in Sweden who possess such extensive competence in quality management […]

Keld Søndergaard nominated as new board member

The Board of Xintela AB (publ) announces that Keld Søndergaard has been nominated for election as a new member of the Board at the annual general meeting on the 18th of May 2017. Also proposed for re-election are Greg Batcheller, Karin Wingstrand, Sven Kili and Claes Post. The proposal is supported by shareholders who represent […]

Xintela strengthens business development and reorganizes

Xintela announces today that Thomas Areschoug has been recruited to the business development team as Business Development Manager. In addition, the company is reorganizing in order to develop its projects more efficiently. – We are very pleased to have Thomas Areschoug join the team. His broad international network and experience is exactly what Xintela now […]

Xintela reports positive preclinical results in cancer project

Xintela AB (publ) today announces an update of the company’s projects in regenerative medicine and cancer. All projects are developing in a positive way. New results from the cancer project show that Xintela’s targeting antibody kills glioblastoma cells both in cell studies and in an animal model. Significant progress in the treatment of the brain […]